David Wojciechowski is a Nephrology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5939 Harry Hines Blvd Pod2, Suite 700
Dallas, TX 753902783
Telephone
214-645-1919Registry record last updated 15 Aug 2019.
Clinical trials
- Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
Sponsor: Camille N. Kotton, MD
- Use of DNA Testing and Gene Expression Profiling to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
Sponsor: University of Texas Southwestern Medical Center
- Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression
Sponsor: University of Texas Southwestern Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Pierre Fabre Pharmaceuticals, Inc.Program year20257 payments
- Veloxis Pharmaceuticals, Inc.Program year20253 payments
- Apellis Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
52.9%Calcium channel blocker19.5%Amlodipine Besylate66%Nifedipine Er34%Part D<11 patientsBeta blocker11.7%Carvedilol100%Part D≥11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
22%Corticosteroid13.4%Prednisone100%Part D≥13 patientsProton pump inhibitor8.6%Pantoprazole Sodium100%Part D≥13 patientsAnti-infectives
13.1%Short-acting sulfonamides8.6%Sulfamethoxazole-Trimethoprim100%Part D≥13 patientsCytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor4.5%Valganciclovir Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”